Advertisement

Physiological Principles Underlying Endocrine Therapy of Breast Cancer

  • William Leo McGuire

Abstract

The subject of endocrine therapy for advanced breast cancer is certainly not new. The first demonstration of hormonal control of breast cancer was made 81 years ago when regression of metastatic tumor was produced by ovariectomy.(1) Since then, adrenalectomy and hypophysectomy have been used to achieve similar results. These ablative procedures serve to remove sources of circulating hormones which stimulate or support breast tumor growth. Alternatively, breast cancer regression can be achieved by administering large pharmacological doses of estrogen, androgen, progestin, or glucocorticoid. Historically, the choice of endocrine therapy for an individual patient has been in large part empirical, guided by certain clinical features such as menopausal status, free interval, site of the dominant lesion, and the response to any previous endocrine therapy. Since the empirical approach has been extensively reviewed in the literature, I will not dwell upon it further in this chapter. Instead, I refer the reader to several excellent books and chapters on the subject.(2–4)

Keywords

Breast Cancer Endocrine Therapy Mammary Gland Androgen Receptor Glucocorticoid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G.T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases, Lancet 2, 104–107 (1896).Google Scholar
  2. 2.
    T.L. Dao, Ablation therapy for hormone-dependent tumors, Annu. Rev. Med. 23, 1–18 (1972).PubMedGoogle Scholar
  3. 3.
    B. Stoll, Hormonal Management in Breast Cancer, J.B. Lippincott, Philadelphia (1969).Google Scholar
  4. 4.
    J.F. Holland and E. Frei (eds.), Cancer Medicine, Lea and Febiger, Philadelphia (1973).Google Scholar
  5. 5.
    W.L. McGuire, G.C. Chamness, and M.E. Costlow, Progress in endocrinology and metabolism: “Hormone dependence in breast cancer,” Metabolism 23, 75–100 (1974).PubMedGoogle Scholar
  6. 6.
    J. Meites, Relation of prolactin and estrogen to mammary tumorigenesis in the rat, J. Natl. Cancer Inst. 48, 1217–1224 (1972).PubMedGoogle Scholar
  7. 7.
    O.H. Pearson, R.M.L. Murray, G. Mozaffarian, and J. Pensky, in: Prolactin and Carcinogenesis (A.R. Boyns and K. Griffiths, eds.), pp. 154–157, Alpha Omega Alpha, Cardiff, Wales (1972).Google Scholar
  8. 8.
    F. Smithline, L. Sherman, and H.D. Kolodny, Prolactin and breast carcinoma, N. Engl. J. Med. 292, 783–792 (1975).Google Scholar
  9. 9.
    O.H. Pearson, O. Llerena, L. Llerena, A. Molina, and T.P. Butler, Prolactin dependent rat mammary cancer: A model for man? Trans. Assoc. Am. Physicians 82, 225–238 (1969).PubMedGoogle Scholar
  10. 10.
    H. Nagasawa and R. Yanai, Effects of prolactin or growth hormones on growth of carcinogen-induced mammary tumors of adreno-ovariectomized rats, Int. J. Cancer 6, 488–495 (1970).PubMedGoogle Scholar
  11. 11.
    A.E. Bogden, D.J. Taylor, E.Y.H Kuo, M.M. Mason, and A. Speropoulos, The effect of pherphenazine-induced serum prolactin response on estrogen-primed mammary tumor-host systems, 13762 and R-35 mammary adenocarcinomas, Cancer Res. 34, 3018–3025 (1974).PubMedGoogle Scholar
  12. 12.
    J. Meites, C.S. Nicholl, and P.K. Talwalker, in: Advances in Neuroendocrinology (A.V. Nalbandov, ed.), pp. 238–288, University of Illinois Press, Urbana (1963).Google Scholar
  13. 13.
    J.A. Clemens, C.W. Welsch, and J. Meites, Effects of hypothalamic lesions on incidence and growth of mammary tumors in carcinogen-treated rats, Proc. Soc. Exp. Biol. Med. 127, 969–972 (1968).PubMedGoogle Scholar
  14. 14.
    M.S. Klaiber, M. Gruenstein, D.R. Meranze, and M.B. Shimkin, Influence of hypothalamic lesions on the induction and growth of mammary cancers in Sprague-Dawley rats receiving 7,12-Dimethylbenz(a)anthracene, Cancer Res. 29, 999–1001 (1969).PubMedGoogle Scholar
  15. 15.
    H. Nagasawa and J. Meites, Effects of a hypothalamic estrogen implant on growth of carcinogen-induced mammary tumors in rats, Cancer Res. 30, 1327–1329 (1970).PubMedGoogle Scholar
  16. 16.
    J. Meites, K.H. Lu, W. Wuttke, H. Nagasawa, and S.K. Quadri, Recent studies on functions and control of prolactin secretion in rats, Recent Prog. Horm. Res. 28, 471–526 (1972).PubMedGoogle Scholar
  17. 17.
    T.P. Butler and O.H. Pearson, Regression of prolactin-dependent rat mammary carcinoma in response to antihormone treatment, Cancer Res. 31, 817–820 (1971).PubMedGoogle Scholar
  18. 18.
    W. Pierpaoli and E. Sorkin, Inhibition of growth of methycholanthrene-induced mammary carcinoma in rats by anti-adenohypophis serum, Nature 238, 58–59 (1972).Google Scholar
  19. 19.
    K.H. Lu, Y. Koch, and J. Meites, Direct inhibition by ergocornine of pituitary prolactin release, Endocrinology 89, 229–233 (1971).PubMedGoogle Scholar
  20. 20.
    W. Wuttke, E.E. Cassell, and J. Meites, Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF, Endocrinology 88, 737–741 (1971).PubMedGoogle Scholar
  21. 21.
    J.C. Heuson, C. Waelbroeck-Van Gaver, and N. Legros, Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-α-ergocryptine, a suppressor of lactation and nidation, Eur. J. Cancer 6, 353–356 (1970).PubMedGoogle Scholar
  22. 22.
    E.E. Cassell, J. Meites, and C.W. Welsch, Effects of ergocornine and ergocryptine on growth of 7,12-Dimethylbenzanthracene-induced mammary tumors in rats, Cancer Res. 31, 1051–1053 (1971).PubMedGoogle Scholar
  23. 23.
    H. Stahelin, B. Burckhardt-Vischer, and E. Fluckiger, Rat mammary cancer inhibition by a prolactin suppressor, 2-Bromo-α-Ergocryptine, Experientia 27, 915–916 (1971).Google Scholar
  24. 24.
    S.K. Quadri and J. Meites, Regression of spontaneous mammary tumors in rats by ergot drugs, Proc. Soc. Exp. Biol. Med. 138, 999–1001 (1971).PubMedGoogle Scholar
  25. 25.
    J.A. Clemens and C.J. Shaar, Inhibition by ergocornine of initiation and growth of 7,12-Dimethylbenzanthracene-induced mammary tumors in rats: Effect of tumor size, Proc. Soc. Exp. Biol. Med. 139, 659–662 (1972).PubMedGoogle Scholar
  26. 26.
    C.W. Welsch, G. Iturri, and J. Meites, Comparative effects of hypophysectomy, ergocornine and ergocornine-reserpine treatments on rat mammary carcinoma, Int. J. Cancer 12, 206–212 (1973).PubMedGoogle Scholar
  27. 27.
    S.K. Quadri, J.L. Clark, and J. Meites, Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats, Proc. Soc. Exp. Biol. Med. 142, 22–26 (1973).PubMedGoogle Scholar
  28. 28.
    S.K. Quadri, G.S. Kledzik, and J. Meites, Effects of l-Dopa and methyldopa on growth of mammary cancers in rats, Proc. Soc. Exp. Biol. Med. 142, 759–761 (1973).PubMedGoogle Scholar
  29. 29.
    H.G. Floss, J.M. Cassady, and J.E. Robbers, Influence of ergot alkaloids on pituitary prolactin and prolactin-dependent processes, J. Pharm. Sci. 62, 699–715 (1973).PubMedGoogle Scholar
  30. 30.
    S. Young, Induction of mammary carcinoma in hypophysectomized rats treated with 3-methylcholanthrene, oestradiol-17β, progesterone and growth hormone, Nature 190, 356–357 (1961).PubMedGoogle Scholar
  31. 31.
    C.H. Li and W. Yang, The effect of bovine growth hormone on growth of mammary tumors in hypophysectomized rats, Life Sci. 15, 761–764 (1975).Google Scholar
  32. 32.
    D. Sinha, D. Cooper, and T.L. Dao, The nature of estrogen and prolactin effect on mammary tumorigenesis, Cancer Res. 33, 411–414 (1973).PubMedGoogle Scholar
  33. 33.
    T.L. Dao and H. Sunderland, Mammary carcinogenesis by 3-methylcholanthrene. 1. Hormonal aspects in tumor induction and growth, J. Natl. Cancer Inst. 23, 567–586 (1959).PubMedGoogle Scholar
  34. 34.
    C. Huggins, R.C. Moon, and S. Morii, Extinction of experimental mammary cancer. I. Estradiol-17β and progesterone, Proc. Natl. Acad. Sci. U.S.A. 48, 379–386 (1962).PubMedGoogle Scholar
  35. 35.
    G.M. McCormick and R.C. Moon, Effect of pregnancy and lactation on growth of mammary tumours induced by 7,12-Dimethylbenz(A)anthracene (DMBA), Br. J. Cancer 19, 160–166 (1965).PubMedGoogle Scholar
  36. 36.
    H. Nagasawa and R. Yanai, Effect of human placental lactogen on growth of carcinogen-induced mammary tumors in rats, Int. J. Cancer 11, 131–137 (1973).PubMedGoogle Scholar
  37. 37.
    G.M. McCormick and R.C. Moon, Hormones influencing postpartum growth of 7,12-Dimethylbenz(a)anthracene-induced rat mammary tumors, Cancer Res. 27, 626–631 (1967).PubMedGoogle Scholar
  38. 38.
    G.M. McCormick, The effect of varying the length of the nursing period on the postpartum growth of chemically induced rat mammary tumors, Cancer Res. 32, 1574–1576 (1972).PubMedGoogle Scholar
  39. 39.
    H. Tomogane, K. Ota, and A. Yokoyama, Suppression of progesterone secretion in lactating rats by administration of ergocornine and the effect of prolactin replacement, J. Endocrinol. 65, 155–161 (1975).PubMedGoogle Scholar
  40. 40.
    W.R. Miller, Hyperprolactinemia and steroid metabolism by rat mammary adenocarcinomas, Cancer Res. 36, 336–338 (1976).PubMedGoogle Scholar
  41. 41.
    R. Luft, H. Olivecrona, and B. Sjogren, Hypotysektomi pa narriska, Nord. Med. 47, 351–354 (1952).PubMedGoogle Scholar
  42. 42.
    O.H. Pearson, C.D. West, V.P. Hollander, and N.E. Treves, Evaluation of endocrine therapy for advanced breast cancer, J. Am. Med. Assoc. 154, 234–239 (1954).PubMedGoogle Scholar
  43. 43.
    O.H. Pearson, B.S. Ray, C. C. Harrold, C.D. West, M.D. Li, J.P. McClean, and M.B. Lipsett, Hypophysectomy in treatment of advanced cancer, Trans. Assoc. Am. Physicians 68, 101–111 (1955).PubMedGoogle Scholar
  44. 44.
    O.H. Pearson and B.S. Ray, Results of hypophysectomy in the treatment of metastatic mammary carcinoma, Cancer 12, 85–92 (1959).PubMedGoogle Scholar
  45. 45.
    M.B. Lipsett and D.M. Bergenstal, Lack of effect of human growth hormone and ovine prolactin on cancer in man, Cancer Res. 20, 1172–1178 (1960).PubMedGoogle Scholar
  46. 46.
    W.B. Malarkey, L.S. Jacobs, and W.H. Daughaday, Levodopa suppression of prolactin in nonpeurperal galactorrhea, N. Engl. J. Med. 285, 1160–1163 (1971).PubMedGoogle Scholar
  47. 47.
    D.L. Kleinberg, G.L. Noel, and A. Frantz, Chlorpromazine stimulation and l-Dopa suppression of plasma prolactin in man, J. Clin. Endocrinol. Metab. 33, 873–876 (1971).Google Scholar
  48. 48.
    H.G. Friesen, H. Guyda, P. Hwang, J.E. Tyson, and A. Barbeau, Functional evaluation of prolactin secretion: A guide to therapy, J. Clin. Invest. 51, 706–709 (1972).PubMedGoogle Scholar
  49. 49.
    R.P. Dickey and J.P. Minton, 1-Dopa effect on prolactin, follicle-stimulating hormone, and luteinizing hormone in women with advanced breast cancer: A preliminary report, Am. J. Obstet. Gynecol. 114, 267–269 (1972).PubMedGoogle Scholar
  50. 50.
    B.A. Stoll, Brain catecholamines in breast cancer: A hypothesis, Lancet 1, 321 (1972).Google Scholar
  51. 51.
    R.M.L. Murray, G. Mozaffarian, and O.H. Pearson, in: Prolactin and Carcinogenesis (A.R. Boyns and K. Griffiths, eds.), pp. 158–161, Alpha Omega Alpha, Cardiff, Wales (1972).Google Scholar
  52. 52.
    A.G. Frantz, D.V. Habif, G.A. Hyman, and H.K. Suh, Remission of metastatic breast cancer after reduction of circulating prolactin in patients treated with l-Dopa, Clin. Res. 20, 864(1972).Google Scholar
  53. 53.
    A.G. Frantz, D.V. Habif, G.A. Hyman, H.K. Suh, J.F. Sassin, E.A. Zimmerman, G.L. Noel, and D.L. Kleinberg, in: Human Prolactin (J.L. Pasteels and C. Robyn, eds.), pp. 273–290, Excerpta Medica, Amsterdam (1973).Google Scholar
  54. 54.
    J.P. Minton, The response of breast cancer patients with bone pain to l-Dopa, Cancer 33, 358–363 (1974).PubMedGoogle Scholar
  55. 55.
    E. del Pozo, R. Brun del Re, L. Varga, and H.G. Friesen, The inhibition of prolactin secretion in man by CB-154 (2-Br-α-ergocryptine), J. Clin. Endocrinol. Metab. 35, 768–771 (1972).PubMedGoogle Scholar
  56. 56.
    L. Lemberger, R. Crabtree, J.A. Clemens, R.W. Dyke, and R.T. Woodburn, The inhibitory effect of an ergoline derivative (Lergotrile, Compound 83636) on prolactin secretion in man, J. Clin. Endocrinol. Metab. 39, 579–584 (1974).PubMedGoogle Scholar
  57. 57.
    R.E. Cleary, R. Crabtree, and L. Lemberger, The effect of lergotrile on galactorrhea and gonadotropin secretion, J. Clin. Endocrinol. Metab. 40, 830–833 (1975).PubMedGoogle Scholar
  58. 58.
    J.E. Tyson, M. Khojandi, J. Huth, B. Smith, and P. Thomas, Inhibition of cyclic gonadotropin secretion by endogenous human prolactin, Am. J. Obstet. Gynecol. 121, 375–379 (1975).PubMedGoogle Scholar
  59. 59.
    J.C Heuson, A. Coume, and M. Staquet, Clinical trial of 2-Br-α-Ergocryptine (CB154) in advanced breast cancer, Eur. J. Cancer 8, 155–156 (1972).Google Scholar
  60. 60.
    P.G. Guerzon and O.H. Pearson, Lergotrile Mesylate, a new prolactin inhibitor drug, Clin. Res. 22, 632A (1974).Google Scholar
  61. 61.
    K.D. Schulz, P.-J. Czygan, E. del Pozo, and H.G. Friesen, in: Human Prolactin (J.L. Pasteels and C. Robyn, eds.), pp. 268–271, Excerpta Medica, Amsterdam (1973).Google Scholar
  62. 62.
    A.R. Boyns, E.N. Cole, K. Griffiths, M.M. Roberts, R. Buchan, R.G. Wilson, and A.P.M. Forrest, Plasma prolactin in breast cancer, Eur. J. Cancer 9, 99–102 (1973).PubMedGoogle Scholar
  63. 63.
    R.G. Wilson, R. Buchan, M.M. Roberts, A.P.M. Forrest, A.R. Boyns, E.N. Cole, and K. Griffiths, Plasma prolactin and breast cancer, Cancer 33, 1325–1327 (1974).PubMedGoogle Scholar
  64. 64.
    H.G. Kwa, M. De Jong-Bakker, E. Engelsman, and F.J. Cleton, Plasma prolactin in human breast cancer, Lancet 1, 433–434 (1974).PubMedGoogle Scholar
  65. 65.
    S. Franks, D.N.L. Ralphs, V. Seagroatt, and H.S. Jacobs, Prolactin concentrations in patients with breast cancer, Br. Med. J. 4, 320–321 (1974).PubMedGoogle Scholar
  66. 66.
    B.E. Henderson, V. Gerkins, I. Rosario, J. Casagrande, and M.C. Pike, Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer, N. Engl. J. Med. 293, 790–795 (1975).PubMedGoogle Scholar
  67. 67.
    Boston Collaborative Drug Surveillance Program, Reserpine and breast cancer, Lancet 2, 669–671 (1974).Google Scholar
  68. 68.
    B. Armstrong, N. Stevens, and R. Doll, Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women, Lancet 2, 672–675 (1974).PubMedGoogle Scholar
  69. 69.
    O.P. Heinomen, S. Shapiro, L. Tuominen, and M.I. Turunen, Resperine use in relation to breast cancer, Lancet 2, 675–677 (1974).Google Scholar
  70. 70.
    T.M. Mack, B.E. Henderson, V.R. Gerkins, M. Arthur, J. Baptista, and M.C. Pike, Reserpine and breast cancer in a retirement community, N. Engl. J. Med. 292, 1366–1371 (1975).PubMedGoogle Scholar
  71. 71.
    W.M. O’Fallon, D.R. Labarthe, and L.T. Kurland, Rauwolfia derivatives and breast cancer, Lancet 2, 292–296 (1975).PubMedGoogle Scholar
  72. 72.
    J.F. Sassin, A.G. Frantz, E.D. Weitzman, and S. Kapen, Human prolactin: 24 hour pattern with increased release during sleep, Science 177, 1205–1207 (1972).PubMedGoogle Scholar
  73. 73.
    J.F. Sassin, A.G. Frantz, S. Kapen, and E.D. Weitzman, The nocturnal rise of human prolactin is dependent on sleep, J. Clin. Endocrinol. Metab. 37, 436–440 (1973).PubMedGoogle Scholar
  74. 74.
    G. Ehni and N.E. Eckles, Interruption of the pituitary stalk in the patient with mammary cancer, J. Neurosurg. 16, 628–652 (1959).PubMedGoogle Scholar
  75. 75.
    R.W. Turkington, L.E. Underwood, and J.J. Van Wyk, Elevated serum prolactin levels after pituitary-stalk section in man, N. Engl. J. Med. 285, 707–710 (1971).PubMedGoogle Scholar
  76. 76.
    R.W. Turkington, G.C. Majumder, N. Kadohama, J.H. MacIndoe, and W.L. Frantz, Hormonal regulation of gene expression in mammary cells, Recent Prog. Horm. Res. 29, 417–455(1973).PubMedGoogle Scholar
  77. 77.
    G.N. Gill, Mechanism of ACTH action, Metabolism 21, 571–588 (1972).PubMedGoogle Scholar
  78. 78.
    R.W. Turkington, Stimulation of RNA synthesis in isolated mammary cells by insulin and prolactin bound to sepharose, Biochem. Biophys. Res. Commun. 41, 1362–1367 (1970).PubMedGoogle Scholar
  79. 79.
    M. Birkinshaw and I.R. Falconer, The localization of prolactin-labelled with radioactive iodine in rabbit mammary tissue, J. Endocrinol. 55, 323–334 (1972).PubMedGoogle Scholar
  80. 80.
    H. Rajaniemi, A. Okasanen, and T. Vanha-Perttula, Distribution of 125I-prolactin in mice and rats. Studies with whole-body and microautoradiography, Horm. Res. 5, 6–20 (1974).PubMedGoogle Scholar
  81. 81.
    R.W. Turkington, Measurement of prolactin activity in human serum by the induction of specific milk proteins in mammary gland in vitro, J. Clin. Endocrinol. Metab. 33, 210–216 (1971).Google Scholar
  82. 82.
    R.P.C. Shiu, P.A. Kelly, and H.G. Friesen, Radioreceptor assay for prolactin and other lactogenic hormones, Science 180, 968–970 (1973).PubMedGoogle Scholar
  83. 83.
    W.L. Frantz, J.H. MacIndoe, and R.W. Turkington, Prolactin receptors: characteristics of the particulate fraction binding activity, J. Endocrinol. 60, 485–497 (1974).PubMedGoogle Scholar
  84. 84.
    R.P.C. Shiu and H.G. Friesen, Properties of a prolactin receptor from the rabbit mammary gland, Biochem. J. 140, 301–311 (1974).PubMedGoogle Scholar
  85. 85.
    B.I. Posner, P.A. Kelly, R.P.C. Shiu, and H.G. Friesen, Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization, Endocrinology 95, 521–531 (1974).PubMedGoogle Scholar
  86. 86.
    M.E. Costlow, R.A. Buschow, N.J. Richert, and W.L. McGuire, Prolactin and estrogen binding in transplantable hormone-dependent and autonomous rat mammary carcinoma, Cancer Res. 35, 970–974 (1975).PubMedGoogle Scholar
  87. 87.
    P.A. Kelly, C. Bradley, R.P.C. Shiu, J. Meites, and H.G. Friesen, Prolactin binding to rat mammary tumor tissue, Proc. Soc. Exp. Biol. Med. 146, 816–819 (1974).PubMedGoogle Scholar
  88. 88.
    E.R. DeSombre, G. Kledzik, S. Marshall, and J. Meites, Estrogen and prolactin receptor concentration in rat mammary tumors and response to endocrine ablation, Cancer Res. 36, 354–358(1976).PubMedGoogle Scholar
  89. 89.
    R.W. Turkington, Prolactin receptors in mammary carcinoma cells, Cancer Res. 34, 758–763 (1974).PubMedGoogle Scholar
  90. 90.
    M.E. Costlow, R.A. Buschow, and W.L. McGuire, Prolactin receptors in an estrogen receptor-deficient mammary carcinoma, Science 184, 85–86 (1974).PubMedGoogle Scholar
  91. 91.
    H.H. Holcomb, M.E. Costlow, R.A. Buschow, and W.L. McGuire, Prolactin binding in rat mammary gland during pregnancy and lactation, Biochim. Biophys. Acta 428, 104–112 (1976).PubMedGoogle Scholar
  92. 92.
    M.E. Costlow, R.A. Buschow, and W.L. McGuire, Prolactin receptors and androgen induced regression of DMBA-induced mammary carcinoma, Cancer Res. 36, 3324–3329 (1976).PubMedGoogle Scholar
  93. 93.
    I.M. Holdaway and H.G. Friesen, Correlation between hormone binding and growth response of rat mammary tumor, Cancer Res. 36, 1562–1567 (1976).PubMedGoogle Scholar
  94. 94.
    G.H. Sasaki and B.S. Leung, Prolactin stimulation of estrogen receptor in vitro in 7,12-Dimethylbenz(A)anthracene-induced mammary tumor, Res. Commun. Chem. Pathol. Pharmacol. 8, 409–412 (1974).PubMedGoogle Scholar
  95. 95.
    F. Vignon and H. Rochefort, Régulation des “réceptors” des oestrogines dans les tumeurs mammaires: effet de la prolactine in vivo, C. R. Acad. Sci. 278, 103–106 (1974).Google Scholar
  96. 96.
    F. Vignon and H. Rochefort, Regulation of estrogen receptors in ovarian-dependent rat mammary tumors. I. Effects of castration and prolactin, Endocrinology 98, 722–729 (1976).PubMedGoogle Scholar
  97. 97.
    E.J. Diamond, S. Koprak, S.K. Shen, and V.P. Hollander, The conversion of an ovariectomy-nonresponsive to an ovariectomy-responsive mammary tumor strain, Cancer Res. 36, 77–80 (1976).PubMedGoogle Scholar
  98. 98.
    B.I. Posner, P.A. Kelly, and H.G. Friesen, Induction of a lactogenic receptor in rat liver: Influence of estrogen and the pituitary, Proc. Natl. Acad. Sci. U.S.A. 71, 2407–2410 (1974).PubMedGoogle Scholar
  99. 99.
    B.I. Posner, P.A. Kelly, and H.G. Friesen, Prolactin receptors in rat liver: Possible induction by prolactin, Science 188, 57–59 (1975).PubMedGoogle Scholar
  100. 100.
    M.E. Costlow, R.A. Buschow, and W.L. McGuire, Prolactin stimulation of prolactin receptors in rat liver, Life. Sci. 17, 1457–1466 (1975).PubMedGoogle Scholar
  101. 101.
    M. Gelato, S. Marshall, M. Boudreau, J. Bruni, and G.A. Campbell, Effects of thyroid and ovaries on prolactin binding in rat liver, Endocrinology 96, 1292–1296 (1975).PubMedGoogle Scholar
  102. 102.
    R. Hilf, I. Michel, and C. Bell, Biochemical and morphological responses of normal and neoplastic mammary tissue to hormonal treatment, Recent Prog. Horm. Res. 23, 229–295 (1967).PubMedGoogle Scholar
  103. 103.
    W.L. McGuire, Hormonal stimulation of lactose synthetase in mammary carcinoma, Science 165, 1013–1014 (1969).PubMedGoogle Scholar
  104. 104.
    N.J. Nardacci and W.L. McGuire, A specific marker for prolactin responsiveness in experimental breast cancer: Lactalbumin mRNA, Clin. Res. 24, 462A (1976).Google Scholar
  105. 105.
    W.L. McGuire, J.A. Julian, and G.C. Chamness, A dissociation between ovarian dependent growth and estrogen sensitivity in mammary carcinoma, Endocrinology 89, 969–973 (1971).PubMedGoogle Scholar
  106. 106.
    W.L. McGuire, K. Huff, A.W. Jennings, and G.C. Chamness, Mammary carcinoma: A specific biochemical defect in autonomous tumors, Science 175, 335–336 (1972).PubMedGoogle Scholar
  107. 107.
    I. Schorr, P. Rathnam, B.B. Saxena, and R.L. Ney, Multiple specific hormone receptors in the adenylate cyclase of an adrenocortical carcinoma, J. Biol. Chem. 246, 5806–5811 (1971).PubMedGoogle Scholar
  108. 108.
    W.R. Lyons, C.H. Li, and R.E. Johnson, The hormonal control of mammary growth and lactation, Recent Prog. Horm. Res. 14, 219–254 (1958).PubMedGoogle Scholar
  109. 109.
    K. Ahren and D. Jacobsohn, Mammary gland growth in hypophysectomized rats injected with ovarian hormones and insulin, Acta Physiol. Scand. 37, 190–203 (1956).PubMedGoogle Scholar
  110. 110.
    A. Norgren, Action of different doses of oestrone on mammary gland of hypophysectomized castrated rabbits, Acta Univ. Lund. 1, 1–24 (1967).Google Scholar
  111. 111.
    H. Nagasawa and R. Yanai, Increased mammary gland response to pituitary mammotropic hormones by estrogen in rats, Endocrinol. Jpn. 18, 53–56 (1971).Google Scholar
  112. 112.
    J. Meites and C.S. Nicoll, Adenhypophysis: Prolactin, Annu. Rev. Physiol. 28, 57–88 (1966).PubMedGoogle Scholar
  113. 113.
    A. Sterental, J.M. Dominguez, C. Weissman, and O.H. Pearson, Pituitary role in the estrogen dependency of experimental mammary cancer, Cancer Res. 23, 481–484 (1963).PubMedGoogle Scholar
  114. 114.
    C.J. Bradley, G.S. Kledzik, and J. Meites, Prolactin and estrogen dependency of rat mammary cancers at early and late stages of development, Cancer Res. 36, 312–324 (1976).Google Scholar
  115. 115.
    S.-I. Murota and V.P. Hollander, Role of ovarian hormones in the growth of transplantable mammary carcinoma, Endocrinology 89, 560–564 (1971).PubMedGoogle Scholar
  116. 116.
    B.V. Caldwell, S.A. Tillson, H. Esber, and I.H. Thorneycroft, Survival of tumours after immunization against oestrogens, Nature 231, 118–119 (1971).PubMedGoogle Scholar
  117. 117.
    O.H. Pearson and H. Nasr, Hormonal steroids, Excerpta Med. Int. Congr. Ser. 219, 602 (1970).Google Scholar
  118. 118.
    H. Nagasawa and R. Yanai, Reduction of pituitary isograft of inhibitory effect of large dose of estrogen on incidence of mammary tumors induced by carcinogen in ovariectomized rats, Int. J. Cancer 8, 463–467 (1971).PubMedGoogle Scholar
  119. 119.
    J. Meites, E.E. Cassell, and J.H. Clark, Estrogen inhibition of mammary tumor growth in rats; counteraction by prolactin, Proc. Soc. Exp. Biol. Med. 137, 1225–1227 (1971).PubMedGoogle Scholar
  120. 120.
    R.F. Glascock and W.G. Hoekstra, Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep, Biochem. J. 72, 673–682 (1959).PubMedGoogle Scholar
  121. 121.
    E.V. Jensen and H.I. Jacobson, in: Biological Activities of Steroids in Relation to Cancer (G. Pincus and E.P. Vollmer, eds.), pp. 161–178, Academic Press, New York (1960).Google Scholar
  122. 122.
    P.J. Folca, R.F. Glascock, and W.T. Irvine, Studies with tritium-labelled hexoestrol in advanced breast cancer, Lancet 2, 796–502 (1961).PubMedGoogle Scholar
  123. 123.
    W.H. Pearlman, R. De Hertogh, K.R. Laumas, and M.R.S. Pearlman, Metabolism and tissue uptake of estrogen in women with advanced carcinoma of the breast, J. Clin. Endocrinol. Metab. 29, 707–720 (1969).PubMedGoogle Scholar
  124. 124.
    F.G. Ellis, T.V. Berne, N. Deshpande, F.O. Beizer, and R.D. Bulbrook, The uptake of tritiated steroids by human breast carcinoma, Surg. Gynecol. Obstet. 128, 975–984 (1969).PubMedGoogle Scholar
  125. 125.
    F. James, V.H.T. James, A.E. Carter, and W.T. Irvine, A comparison of in vivo and in vitro uptake of estradiol by human breast tumors and the relationship of steroid excretion, Cancer Res. 31 1268–1272 (1971).PubMedGoogle Scholar
  126. 126.
    H. Braunsberg, V.H.T. James, W.T. Irvine, C.W. Jamieson, F. James, R.A. Sellwood, A.E. Carter, and M. Hulbert, Prognostic significance of oestrogen uptake by human breast cancer tissue, Lancet 1, 163–165 (1973).PubMedGoogle Scholar
  127. 127.
    R.J.B. King, D.M. Cowan, and D.R. Inman, The uptake of [6,7-3H]oestradiol by dimethylbenzanthracene-induced rat mammary tumours, J. Endocrinol. 32, 83–90 (1965).PubMedGoogle Scholar
  128. 128.
    R.J.B. King, J. Gordon, D.M. Cowan, and D.R. Inman, The intranuclear localization of [6,7-3H]oestradiol-17β in dimethylbenzanthracene-induced rat mammary adenocarcinoma and other tissues, J. Endocrinol. 36, 139–150 (1966).PubMedGoogle Scholar
  129. 129.
    B.G. Mobbs, The uptake of tritiated oestradiol by dimethylbenzanthracene-induced mammary tumours of the rat, J. Endocrinol. 36, 409–414 (1966).PubMedGoogle Scholar
  130. 130.
    S. Sander and A. Attramadal, The in vivo uptake of oestradiol-17β by hormone responsive and unresponsive breast tumors of the rat, Acta Pathol. Microbiol. Scand. 74, 169–178 (1968).PubMedGoogle Scholar
  131. 131.
    L. Terenius, Parallelism between oestrogen binding capacity and hormone responsiveness of mammary tumours in GR/A mice, Eur. J. Cancer 8, 55–58 (1972).PubMedGoogle Scholar
  132. 132.
    B.G. Mobbs, Uptake of [3H]oestradiol by dimethylbenzanthracene-induced rat mammary tumours regressing spontaneously or after ovariectomy, J. Endocrinol. 44, 463–464 (1969).PubMedGoogle Scholar
  133. 133.
    E.V. Jensen, E.R. DeSombre, and P.W. Jungblut, in: Endogenous Factors Influencing Host-Tumor Balance (R.W. Wissler, T.L. Dao, and S. Wood, Jr., eds.), pp. 15–30, University of Chicago Press, Chicago (1967).Google Scholar
  134. 134.
    L. Terenius, Selective retention of estrogen isomers in estrogen dependent breast tumors of rats demonstrated by in vitro methods, Cancer Res. 28, 328–337 (1968).PubMedGoogle Scholar
  135. 135.
    E.V. Jensen and E.R. DeSombre, Mechanism of action of the female sex hormones, Annu. Rev. Biochem. 41, 203–230 (1972).PubMedGoogle Scholar
  136. 136.
    J. Gorski, D.O. Toft, G. Shyamala, D. Smith, and A. Notides, Hormone receptors: Studies on the interaction of estrogen with the uterus, Recent Prog. Horm. Res. 24 45–80 (1968).PubMedGoogle Scholar
  137. 137.
    G.C. Mueller, B. Vonderhaar, U.H. Kim, and M.L. Mahieu, Estrogen action: An inroad to cell biology, Recent Prog. Horm. Res. 28, 1–49 (1972).PubMedGoogle Scholar
  138. 138.
    F. Bresciani, G.A. Puca, E. Nola, M. Salvatore, and I. Ardovino, Meccanismo dell’azione estrogena e transformazione neoplastica, Atti Soc. Ital. Patol. 11, 203–224 (1969).Google Scholar
  139. 139.
    W.L. McGuire and J.A. Julian, Comparison of macromolecular binding of estradiol in hormone dependent and hormone independent rat mammary carcinoma, Cancer Res. 31, 1440–1445 (1971).PubMedGoogle Scholar
  140. 140.
    W.L. McGuire, P.P. Carbone, M.E. Sears, and G.C. Escher, in: Estrogen Receptors in Human Breast Cancer (W.L. McGuire, P.P. Carbone, and E.P. Vollmer, eds.), pp. 1–7, Raven Press, New York (1975).Google Scholar
  141. 141.
    S.G. Korenman, Estrogen receptor assay in human breast cancer, J. Natl. Cancer Inst. 55, 543–545 (1975).PubMedGoogle Scholar
  142. 142.
    G.C. Chamness, K. Huff, and W.L. McGuire, Protamine-precipitated estrogen receptor: A solid-phase ligand exchange assay, Steroids 25, 627–635 (1975).PubMedGoogle Scholar
  143. 143.
    D.T. Zava, N.Y. Harrington, and W.L. McGuire, A nuclear exchange assay for estradiol receptor, Biochemistry 15, 4292–4297 (1976).PubMedGoogle Scholar
  144. 144.
    B.S. Leung and G.H. Sasaki, On the mechanism of prolactin and estrogen action in 7,12-Dimethylbenz(A)anthracene-induced mammary carcinoma in the rat. II. In vivo tumor responses and estrogen receptor, Endocrinology 97, 564–572 (1975).PubMedGoogle Scholar
  145. 145.
    Y. Nomura, Y. Abe, and K. Inokuchi, Specific estrogen receptor and its relation to response to oophorectomy in rat mammary cancer induced by 7,12-Dimethylbenz(a)anthracene, Gann 65, 523–528 (1974).PubMedGoogle Scholar
  146. 146.
    G. Shyamala, Estradiol receptors in mouse mammary tumors—absence of the transfer of bound estradiol from the cytoplasm to the nucleus, Biochem. Biophys. Res. Commun. 46, 1623–1630 (1972).PubMedGoogle Scholar
  147. 147.
    F. Vignon and H. Rochefort, Estrogen receptor studies in experimental tumors, in: Proc. 10th Meeting on Mammary Cancer, Kobe, Japan, p. 42 (1976).Google Scholar
  148. 148.
    W.L. McGuire, K. Huff, and G.C. Chamness, Temperature dependent binding of estrogen receptor to chromatin, Biochemistry 11, 4562–4565 (1972).PubMedGoogle Scholar
  149. 149.
    W.L. McGuire and M. De La Garza, Similarity of the estrogen receptor in human and rat mammary carcinoma, J. Clin. Endocrinol. Metab. 36, 548–552 (1973).PubMedGoogle Scholar
  150. 150.
    W.L. McGuire, Estrogen receptors in human breast cancer, J. Clin. Invest. 52, 73–77 (1973).PubMedGoogle Scholar
  151. 151.
    W.L. McGuire and M. De La Garza, Improved sensitivity in the measurement of estrogen receptor in human breast cancer, J. Clin. Endocrinol. Metab. 37, 986–989 (1973).PubMedGoogle Scholar
  152. 152.
    W.L. McGuire, O.H. Pearson, and A. Segaloff, in: Estrogen Receptors in Human Breast Cancer (W.L. McGuire, P.P. Carbone, and E.P. Vollmer, eds.), pp. 17–30, Raven Press, New York (1975).Google Scholar
  153. 153.
    P.P. Rosen, C.J. Mendendez-Bolet, J.S. Nisselbaum, J.A. Urban, V. Mike, A. Fracchia, and M.K. Schwartz, Pathological review of breast lesions analyzed for estrogen receptor protein, Cancer Res. 35, 3187–3194 (1975).PubMedGoogle Scholar
  154. 154.
    P. Feherty, G. Fairer-Brown, and A.E. Kellie, Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay, Br. J. Cancer 25, 697–710 (1971).PubMedGoogle Scholar
  155. 155.
    S.G. Korenman and B.A. Dukes, Specific estrogen binding by the cytoplasm of human breast carcinoma, J. Clin. Endocrinol. Metab. 30, 639–645 (1970).PubMedGoogle Scholar
  156. 156.
    R. Hahnel, E. Twaddle, and A.B. Vivian, Estrogen receptors in human breast cancer. II. In vitro binding of estradiol by benign and malignant tumors, Steroids 18, 681–708 (1971).PubMedGoogle Scholar
  157. 157.
    G.A. Puca and F. Bresciani, Interactions of 6,7-3H-17β-estradiol with mammary gland and other organs of the C3H mouse in vivo, Endocrinology 85, 1–10 (1969).Google Scholar
  158. 158.
    J.L. Wittliff, D.G. Gardner, W.L. Battema, and P.J. Gilbert, Specific estrogen-receptors in the neoplastic and lactating mammary gland of the rat, Biochem. Biophys. Res. Commun. 48, 119–125 (1972).PubMedGoogle Scholar
  159. 159.
    G. Shyamala and S. Nandi, Interactions of 6,7-3H-17β-estradiol with the mouse lactating mammary tissue in vivo and in vitro, Endocrinology 91, 861–867 (1972).Google Scholar
  160. 160.
    A.J.W. Hsueh, E.J. Peck, Jr., and J. H. Clark, Oestrogen receptors in the mammary gland of the lactating rat, J. Endocrinol 58, 503–511 (1973).PubMedGoogle Scholar
  161. 161.
    J.A. Katzenellenbogen, H.J. Johnson, and K.E. Carlson, Studies on the uterine, cytoplasmic estrogen binding protein. Thermostability and ligand dissociation rate. An assay of empty and filled sites by exchange, Biochemistry 12, 4092–4099 (1973).PubMedGoogle Scholar
  162. 162.
    H. Truong, C. Geynet, C. Millet, O. Soulignac, R. Boucourt, M. Vignau, V. Torelli, and E.E. Baulieu, Purification of estradiol receptor by affinity chromatography. Representative experiments, FEBS Lett. 35, 289–294 (1973).PubMedGoogle Scholar
  163. 163.
    J.L. Daehnfeldt, Endogenously blocked high affinity estradiol receptors in the immature and mature rat uterus, Proc. Soc. Exp. Biol. Med. 146, 159–162 (1974).PubMedGoogle Scholar
  164. 164.
    K.B. Horwitz, M.E. Costlow, and W.L. McGuire, MCF-7: A human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors, Steroids 26, 785–795 (1975).PubMedGoogle Scholar
  165. 165.
    K.B. Horwitz, W.L. McGuire, O.H. Pearson, and A. Segaloff, Predicting response to endocrine therapy in human breast cancer: A hypothesis, Science 189, 726–727 (1975).PubMedGoogle Scholar
  166. 166.
    R.E. Buller, W.T. Schrader, and B.W. O’Malley, Progesterone-binding components of chick oviduct, J. Biol. Chem. 250, 809–818 (1975).PubMedGoogle Scholar
  167. 167.
    G.C. Chamness, A.W. Jennings, and W.L. McGuire, Oestrogen receptor binding is not restricted to target nuclei, Nature 241, 458–460 (1973).PubMedGoogle Scholar
  168. 168.
    G.C. Chamness, A.W. Jennings, and W.L. McGuire, Estrogen receptor binding to isolated nuclei. A nonsaturable process, Biochemistry 13, 327–331 (1974).PubMedGoogle Scholar
  169. 169.
    R.E. Shepherd, K. Huff, and W.L. McGuire, Non-interaction between in vivo and cell free nuclear binding of estrogen receptor, Endocr. Res. Commun. 1, 73–85 (1974).PubMedGoogle Scholar
  170. 170.
    J.H. Clark and E.J. Peck, Nuclear retention of receptor-oestrogen complex and nuclear acceptor sites, Nature 260, 635–637 (1976).PubMedGoogle Scholar
  171. 171.
    D.T. Zava, G.C. Chamness, K.B. Horwitz, and W.L. McGuire, Human breast cancer: Biologically active estrogen receptor in the absence of estrogen? Science (1977), in press.Google Scholar
  172. 172.
    K.D. Schulz, B. Haselmeier, and F. Holzel, The influence of Clomid and its isomers upon dimethylbenzanthracene-induced rat mammary tumours, Acta Endocrinol. Suppl. 138, 236(1969).Google Scholar
  173. 173.
    L. Terenius, Anti-oestrogens and breast cancer, Eur. J. Cancer 7, 57–64 (1971).PubMedGoogle Scholar
  174. 174.
    E. DeSombre and L.Y. Arbogast, Effect of the antiestrogen CI 628 on the growth of rat mammary tumors, Cancer Res. 34, 1971–1976 (1974).PubMedGoogle Scholar
  175. 175.
    V.C. Jordan and S. Koerner, Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin, J. Endocrinol. 68, 305–311 (1976).PubMedGoogle Scholar
  176. 176.
    G.H. Gallez, J.C. Heuson, and C.H. Waelbroeck, Growth-stimulating effect of nafoxidine on rat mammary tumor after ovariectomy, Eur. J. Cancer 9, 699–700 (1973).PubMedGoogle Scholar
  177. 177.
    J.C. Heuson, C. Waelbroeck, N. Legros, G. Gallez, C. Robyn, and M. L’Hermite, Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-Br-α-ergocryptine (CB154), an inhibitor of prolactin secretion, and by nafoxidine (U-11,100A) an estrogen antagonist, Gynecol. Invest. 2, 130–137 (1972).Google Scholar
  178. 178.
    V.C. Jordan and T. Jaspan, Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response, J. Endocrinol. 68, 453–460 (1976).PubMedGoogle Scholar
  179. 179.
    M.J. O’Halloran and P.G. Maddock, ICI 46,474 in breast cancer, J. Ir. Med. Assoc. 67, 38–39 (1974).PubMedGoogle Scholar
  180. 180.
    M.P. Cole, C.T.A. Jones, and I.D.H. Todd, A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474, Br. J. Cancer 25, 270–275 (1971).PubMedGoogle Scholar
  181. 181.
    H.W.C. Ward, Antioestrogen therapy for breast cancer: A trial of tamoxifen at 2 dose levels, Br. Med. J. 1, 13–14 (1973).PubMedGoogle Scholar
  182. 182.
    J. C. Heuson, A. Coume, and M. Staquet (For the E.O.R.T.C. Breast Cancer Group), Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer, Eur. J. Cancer 8, 387–389 (1972).Google Scholar
  183. 183.
    H.J.G. Bloom and E. Boesen, Antioestrogens in treatment of breast cancer: Value of nafoxidine in 52 advanced cases, Br. Med. J. 2, 7–10 (1974).PubMedGoogle Scholar
  184. 184.
    J.C. Heuson, E. Engelsman, J. Blonk-vander Wijst, H. Maass, A. Drochmans, J. Michel, H. Nowakowski, and A. Gorins, Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: An E.O.R.T.C. study, Br. Med. J. 2, 711–713 (1975).PubMedGoogle Scholar
  185. 185.
    E. Hecker, I. Vegh, C.M. Levy, C.A. Magin, J.C Martinez, J. Loureino, and R.E. Garola, Clinical trial of clomiphene in advanced breast cancer, Eur. J. Cancer 10, 747–749 (1974).PubMedGoogle Scholar
  186. 186.
    L. Terenius, Structure-activity relationships of anti-oestrogens with regard to interaction with 17β-oestradiol in the mouse uterus and vagina, Acta Endocrinol 66, 431–447 (1971).PubMedGoogle Scholar
  187. 187.
    H. Rochefort, F. Lignon, and F. Capony, Effect of antiestrogens on uterine estradiol receptors, Gynecol Invest 3, 43–62 (1972).PubMedGoogle Scholar
  188. 188.
    J.H. Clark, J.N. Anderson, and E.J. Peck, Jr., Estrogen receptor-antiestrogen complex: atypical binding by uterine nuclei and effects on uterine growth, Steroids 22, 707–718 (1973).PubMedGoogle Scholar
  189. 189.
    B.S. Katzenellenbogen and E.R. Ferguson, Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen, Endocrinology 97, 1–12 (1975).PubMedGoogle Scholar
  190. 190.
    J.H. Clark, E.J. Peck, Jr., and J. N. Anderson, Oestrogen receptors and antagonism of steroid hormone action, Nature 251, 446–448 (1974).PubMedGoogle Scholar
  191. 191.
    V.C. Jordan and S. Koerner, Tamoxifen (ICI 46,474) and the human carcinoma 8 S oestrogen receptor, Eur. J. Cancer 11, 205–206 (1975).PubMedGoogle Scholar
  192. 192.
    R. Garola, C.M. Levy, I. Vegh, C. Magin, J.C. Martinez, and E. Hecker, In vivo blockade of the estradiol-binding-protein (EBP) by clomiphene citrate in human breast cancer, Oncology 30, 105–112 (1974).Google Scholar
  193. 193.
    M.E. Lippman and G. Bolan, Oestrogen-responsive human breast cancer in long term tissue culture, Nature 256, 592–593 (1975).PubMedGoogle Scholar
  194. 194.
    V.C. Jordan, S. Koerner, and C. Robison, Inhibition of oestrogen-stimulated prolactin release by anti-oestrogens, J. Endocrinol. 65, 151–152 (1975).PubMedGoogle Scholar
  195. 195.
    B.S. Leung, G.H. Sasaki, and J. Leung, Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors, Cancer Res. 35, 621–627 (1975).PubMedGoogle Scholar
  196. 196.
    P. Cole and B. MacMahon, Oestrogen fractions during early reproductive life in the etiology of breast cancer, Lancet 1, 604–606 (1969).PubMedGoogle Scholar
  197. 197.
    B. MacMahon, P. Cole, and J. Brown, Etiology of human breast cancer: A review, J. Natl. Cancer Inst. 50, 21–42 (1973).PubMedGoogle Scholar
  198. 198.
    L.E. Dickinson, B. MacMahon, P. Cole, and J.B. Brown, Estrogen profiles of oriental and Caucasian women in Hawaii, N. Engl. J. Med. 291, 1211–1213 (1974).PubMedGoogle Scholar
  199. 199.
    H.M. Lemon, Endocrine influences on human mammary cancer formation. A critique, Cancer 23, 781–790 (1969).PubMedGoogle Scholar
  200. 200.
    H.M. Lemon, Abnormal estrogen metabolism and tissue estrogen receptor proteins in breast cancer, Cancer 25, 423–435 (1970).PubMedGoogle Scholar
  201. 201.
    H.M. Lemon, D.M. Miller, and J.F. Foley, Competition between steroids for hormonal receptor, Natl. Cancer Inst. Monogr.Prediction of Response in Cancer Therapy 34, 77–83 (1971).Google Scholar
  202. 202.
    H.M. Lemon, Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarlazine, Cancer Res. 35, 1341–1353 (1975).PubMedGoogle Scholar
  203. 203.
    S.G. Korenman, Comparative binding affinity of estrogens and its relation to estrogenic potency, Steroids 13, 163–178 (1969).PubMedGoogle Scholar
  204. 204.
    D.L. Loriaux, H.J. Ruder, D.R. Knab, and M.B. Lipsett, Estrone sulfate, estrone, estradiol and estriol plasma levels in human pregnancy, J. Clin. Endocrinol. Metab. 35, 887–891 (1972).PubMedGoogle Scholar
  205. 205.
    M.B. Lipsett, Oestrogen profiles and breast cancer, Lancet 2, 1378 (1971).PubMedGoogle Scholar
  206. 206.
    T.S. Ruh, B.S. Katzenellenbogen, J.A. Katzenellenbogen, and J. Gorski, Estrone interaction with the rat uterus: in vitro response and nuclear uptake, Endocrinology 92, 125–134 (1973).PubMedGoogle Scholar
  207. 207.
    G. Rudali, F. Apiou, and B. Muel, Mammary cancer produced in mice with estriol, Eur. J. Cancer 11, 39–41 (1975).PubMedGoogle Scholar
  208. 208.
    B.M. Sherman and S.G. Korenman, Inadequate corpus luteum function: A pathophysiological interpretation of human breast cancer epidemiology, Cancer 33, 1306–1312 (1974).PubMedGoogle Scholar
  209. 209.
    J.J. Barlow, K. Emerson, Jr., and B.N. Saxena, Estradiol production after ovariectomy for carcinoma of the breast, N. Engl. J. Med. 280, 633–637 (1969).PubMedGoogle Scholar
  210. 210.
    C. Longcope, Metabolic clearance and blood production rates of estrogens in postmenopausal women, Am. J. Obstet. Gynecol. 111, 778–781 (1971).PubMedGoogle Scholar
  211. 211.
    M.A. Kirschner and J.P. Taylor, Urinary estrogen production rates in normal and endocrine-ablated subjects, J. Clin. Endocrinol. Metab. 35, 513–521 (1972).PubMedGoogle Scholar
  212. 212.
    J.M. Grodin, P.K. Siiteri, and P.C. MacDonald, Source of estrogen production in postmenopausal women, J. Clin. Endocrinol. Metab. 36, 207–214 (1973).PubMedGoogle Scholar
  213. 213.
    H.L. Judd, G.E. Judd, W.E. Lucas, and S.S.C. Yen, Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood, J. Clin. Endocrinol. Metab. 39, 1020–1024 (1974).PubMedGoogle Scholar
  214. 214.
    A. Lipton and R.J. Santen, Medical andrenalectomy using ammoglutethimide and dexamethasone in advanced breast cancer, Cancer 33, 503–512 (1974).PubMedGoogle Scholar
  215. 215.
    R.N. Dexter, L.M. Fishman, R.L. Ney, and G.W. Liddle, Inhibition of adrenal corticosteroid synthesis by ammoglutethimide: Studies of the mechanism of action, J. Clin. Endocrinol. Metab. 27, 473–480 (1967).PubMedGoogle Scholar
  216. 216.
    R.R. Cash, J. Brough, M.N.P. Cohen, and P.S. Satoh, Aminoglutethimide (Elipten-Ciba) as an inhibition of adrenal steroidogenesis: mechanism of action and therapeutic trial, J. Clin. Endocrinol. Metab. 27, 1239–1248 (1967).PubMedGoogle Scholar
  217. 217.
    T. Hall, J.J. Barlow, C.T. Griffiths, and Z. Saba, Treatment of metastatic breast cancer with aminoglutethimide, Clin. Res. 17, 402 (1969).Google Scholar
  218. 218.
    C.T. Griffiths, T.C. Hall, Z. Saba, J.J. Barlow, and H.B. Nevinny, Preliminary trial of aminoglutethimide in breast cancer, Cancer 32, 32–37 (1973).Google Scholar
  219. 219.
    R.J. Santen, A. Lipton, and J. Kendall, Successful medical adrenalectomy with aminoglutethimide: Role of altered drug metabolism, J. Am. Med. Assoc. 230, 1661–1665 (1974).Google Scholar
  220. 220.
    W.E. Poel, Progesterone enhancement of mammary tumor development as a model of co-carcinogenesis, Br. J. Cancer 22, 867–873 (1968).PubMedGoogle Scholar
  221. 221.
    C. Huggins and N.C. Yang, Induction and extinction of mammary cancer, Science 137, 257–262 (1962).PubMedGoogle Scholar
  222. 222.
    C. Huggins, Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference, Cancer Res. 25, 1163–1175 (1965).PubMedGoogle Scholar
  223. 223.
    G.M. McCormick and R.C. Moon, Effect of increasing doses of estrogen and progesterone on mammary carcinogenesis in the rat, Eur. J. Cancer 9, 483–486 (1973).PubMedGoogle Scholar
  224. 224.
    F.M. Muggia, P.A. Casilleth, M. Ochoa, F.A. Flatow, A. Gellhorn, and G.A. Hyman, Treatment of breast cancer with medroxyprogesterone, Ann. Int. Med. 68, 328–337 (1968).PubMedGoogle Scholar
  225. 225.
    B.A. Stoll, Vaginal cytologyas, an aid to hormone therapy in postmenopausal cancer of the breast, Cancer 20, 1807–1813 (1967).PubMedGoogle Scholar
  226. 226.
    Council on Drugs, Androgens and estrogens in the treatment of disseminated mammary carcinoma, J. Am. Med. Assoc. 172, 1271–1283 (1960).Google Scholar
  227. 227.
    L.G. Growley and I. MacDonald, Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal women, Cancer 18, 436–446 (1965).Google Scholar
  228. 228.
    B.A. Stoll, Progestin therapy of breast cancer: Comparison of agents, Br. Med. J. 3, 338–341 (1967).PubMedGoogle Scholar
  229. 229.
    B.A. Stoll, Effect of tyndiol, an oral contraceptive, on breast cancer, Br. Med. J. 1, 150–153 (1967).PubMedGoogle Scholar
  230. 230.
    L. Sadoff and W. Lusk, The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of Cortisol, T4, LH, and testosterone in patients with advanced cancer, Obstet. Gynecol. 43, 262–266 (1974).PubMedGoogle Scholar
  231. 231.
    R.L. Landau, E.N. Ehrlich, and C. Huggins, Estradiol benzoate and progesterone in advanced human breast cancer, J. Am. Med. Assoc. 182, 632–636 (1962).Google Scholar
  232. 232.
    B.J. Kennedy, Hormone therapy for advanced breast cancer, Cancer 18, 1551–1557 (1965).PubMedGoogle Scholar
  233. 233.
    B.J. Kennedy and L. French, Hypophysectomy in advanced breast cancer, Am. J. Surg. 110, 411–414 (1965).PubMedGoogle Scholar
  234. 234.
    M.J. Bryson and M.L. Sweat, Metabolism of progesterone and human myometrium, Endocrinology 84, 1071–1075 (1969).PubMedGoogle Scholar
  235. 235.
    D.T. Armstrong and E.R. King, Uterine progesterone metabolism and progestational response: effects of estrogen and prolactin, Endocrinology 89, 191–197 (1971).PubMedGoogle Scholar
  236. 236.
    I. Hashimoto, D.M. Hendricks, L.L. Anderson, and R.M. Melampy, Progesterone and pregn-4-en-20α-ol-3-one and ovarian venous blood during various reproductive states in the rat, Endocrinology 82, 333–341 (1968).PubMedGoogle Scholar
  237. 237.
    D. Egert and H. Maass, Progesterone in the uterus. III. On the question of progesterone metabolism in the uterus of pregnant rats, Acta Endocrinol 77, 160–170 (1974).PubMedGoogle Scholar
  238. 238.
    W.G. Wiest, in: The Sex Steroids (K.W. McKerns, ed.), pp. 295–313, Plenum Press, New York (1971).Google Scholar
  239. 239.
    J.A. Collins and D.M. Jewkes, Progesterone metabolism by proliferative and secretory human endometrium, Am. J. Obstet. Gynecol. 118, 179–185 (1974).PubMedGoogle Scholar
  240. 240.
    W.G. Wiest, In vitro metabolism of progesterone and 20-α-hydroxypregn-4-en-3-one by tissues of the female rat, Endocrinology 73, 310–316 (1963).PubMedGoogle Scholar
  241. 241.
    D.E.M. Lawson and W.H. Pearlman, The metabolism in vivo of progesterone-7–3H; its localization in the mammary gland, uterus, and other tissues of the pregnant rat, J. Biol. Chem. 239, 3226–3232 (1964).PubMedGoogle Scholar
  242. 242.
    R.T. Chatterton, in: The Sex Steroids (K.W. McKerns, ed.), pp. 345–382, Plenum Press, New York (1971).Google Scholar
  243. 243.
    K.C. Podratz, T.W. Munns, and P.A. Katzman, Metabolism of progesterone and mouse vaginal tissue, Steroids 24, 775–792 (1974).PubMedGoogle Scholar
  244. 244.
    T. Tabei, H. Haga, W.L. Heinrichs, and W.L. Herrmann, Metabolism of progesterone by rat brain, pituitary gland and other tissues, Steroids 23, 651–666 (1974).PubMedGoogle Scholar
  245. 245.
    B.W. O’Malley, W.L. McGuire, P.O. Kohler, and S.G. Korenman, Studies on the mechanism of steroid hormone regulation of synthesis of specific hormones, Recent Prog. Horm. Res. 25, 105–160 (1969).PubMedGoogle Scholar
  246. 246.
    M.D. Morgan and J.D. Wilson, Intranuclear metabolism of progesterone-1,2-3H in the hen oviduct, J. Biol. Chem. 245, 3781–3789 (1970).PubMedGoogle Scholar
  247. 247.
    N. Deshpande, Hormonal imbalance in breast cancer, J. Steroid Biochem. 6, 735–741 (1975).PubMedGoogle Scholar
  248. 248.
    N. Bruchovsky and J.D. Wilson, The conversion of testosterone to 5α-androgen-17β-ol-3-one by rat prostate in vivo and in vitro, J. Biol. Chem. 243, 2012–2021 (1968).Google Scholar
  249. 249.
    J.D. Wilson, Recent studies on the mechanism of action of testosterone, N. Engl. J. Med. 287, 1284–1291 (1972).PubMedGoogle Scholar
  250. 250.
    R.T. Chatterton, Jr., A.J. Chatteron, and L. Hellman, Metabolism of progesterone by the rabbit mammary gland, Endocrinology 85, 16–24 (1969).PubMedGoogle Scholar
  251. 251.
    J. Saffran, B.K. Loeser, B.M. Haas, and H.E. Stavely, Metabolism of progesterone in rat uterus, Steroids 23, 117–131 (1974).PubMedGoogle Scholar
  252. 252.
    W. W. Leavitt and C. J. Grossman, Characterization of binding components for progesterone and 5α-pregnane-3,20-dione in the hamster uterus, Proc. Natl. Acad. Sci. U.S.A. 71, 4341–4345(1974).PubMedGoogle Scholar
  253. 253.
    J.C. Coffey, In vitro progesterone in rat submaxillary gland; the formation of 20α-hydroxy-4-pregnen-3-one and other substances, Steroids 22, 561–566 (1973).PubMedGoogle Scholar
  254. 254.
    C.A. Strott, Metabolism of progesterone in the chick oviduct: relation to the progesterone receptor and biological activity, Endocrinology 95, 826–837 (1974).Google Scholar
  255. 255.
    B.W. O’Malley and W.T. Schrader, Progesterone receptor components: identification of subunits binding to the target-cell genome, J. Steroid Biochem. 3, 617–629 (1972).PubMedGoogle Scholar
  256. 256.
    L.E. Faber, M.L. Sandmann, and H.E. Stavely, Progesterone binding in uterine cytosols of the guinea pig, J. Biol. Chem. 247, 8000–8004 (1972).PubMedGoogle Scholar
  257. 257.
    E. Milgrom, L. Thi, M. Atger, and E.-E. Baulieu, Mechanisms of regulating the concentration and the conformation of progesterone receptor(s) in the uterus, J. Biol. Chem. 248, 6366–6374(1973).PubMedGoogle Scholar
  258. 258.
    M. Atger, E.-E. Baulieu, and E. Milgrom, An investigation of progesterone receptors in guinea pig vagina, uterine cervix, mammary glands, pituitary, and hypothalamus, Endocrinology 94, 161–167 (1974).PubMedGoogle Scholar
  259. 259.
    K. Kontula, O. Jaane, E. Rajakoski, E. Tanhuapaa, and R. Vihko, Ligand specificity of progesterone binding proteins in guinea pig and sheep, J. Steroid Biochem. 5, 39–44 (1974).PubMedGoogle Scholar
  260. 260.
    M.L. Freifeld, P.D. Feil, and C.W. Bardin, The in vivo regulation of the progesterone “receptor” in guinea pig uterus: Dependence on estrogen and progesterone, Steroids 23, 93–103 (1974).PubMedGoogle Scholar
  261. 261.
    D. Philibert and J.-P. Raynaud, Progesterone binding in the immature rabbit and guinea pig, Endocrinology 94, 627–632 (1974).PubMedGoogle Scholar
  262. 262.
    P.D. Feil and C.W. Bardin, Cytoplasmic and nuclear progesterone receptor in the guinea pig uterus, Endocrinology 97, 1398–1407 (1975).PubMedGoogle Scholar
  263. 263.
    W.W. Leavitt, D.O. Toft, C.A. Strott, and B.W. O’Malley, A specific progesterone receptor in the hamster uterus: Physiologic properties and regulation during the estrous cycle, Endocrinology 94, 1041–1053 (1974).PubMedGoogle Scholar
  264. 264.
    L.E. Faber, M.L. Sandmann, and H.E. Stavely, Progesterone binding proteins of the rat and rabbit uterus, J. Biol. Chem. 247, 5648–5649 (1972).PubMedGoogle Scholar
  265. 265.
    L. Faber, M.L. Sandmann, and H. Stavely, Progesterone and corticosterone binding in rabbit uterine cytosols, Endocrinology 93, 74–80 (1973).PubMedGoogle Scholar
  266. 266.
    J. Davies, J.R.G. Challis, and K.J. Ryan, Progesterone receptors and the myometrium of pregnant rabbits, Endocrinology 95, 164–173 (1974).Google Scholar
  267. 267.
    P.D. Feil, S.R. Glasser, D.O. Toft, and B.W. O’Malley, Progesterone binding in the mouse and rat uterus, Endocrinology 91, 738–746 (1972).PubMedGoogle Scholar
  268. 268.
    D. Philibert and J.-P. Raynaud, Progesterone binding in the immature mouse and rat uterus, Steroids 22, 89–99 (1973).PubMedGoogle Scholar
  269. 269.
    J. Saffran, B.K. Loeser, B. Haas, and H.E. Stavely, Binding of progesterone by rat uterus in vitro, Biochem. Biophys. Res. Commun. 53, 202–209 (1973).PubMedGoogle Scholar
  270. 270.
    A.J.W. Hsueh, E.J. Peck, Jr., and J.H. Clark, Receptor progesterone complex in the nuclear fraction of the rat uterus demonstrated by tritiated progesterone exchange, Steroids 24, 599–611 (1974).PubMedGoogle Scholar
  271. 271.
    K. Kontula, O. Janne, T. Luukkainen, and R. Vihko, Progesterone binding protein in human myometrium. Ligand specificity and some physiochemical characteristics, Biochim. Biophys. Acta 328, 145–153 (1973).Google Scholar
  272. 272.
    H.E. Smith, R.G. Smith, D.O. Toft, J.R. Neergaard, E. Burrows, and B.W. O’Malley, Binding of steroids to progesterone receptor proteins in chick oviduct and human uterus, J. Biol. Chem. 249, 5924–5932 (1974).PubMedGoogle Scholar
  273. 273.
    P.C.M. Young and R.E. Cleary, Characterization and properties of progesterone binding components in human endometrium, J. Clin. Endocrinol. Metab. 39, 425–439 (1974).PubMedGoogle Scholar
  274. 274.
    K. Pollow, H. Lubbert, E. Boquoi, G. Kruezer, and B. Pollow, Characterization and comparison of receptors for 17β-estradiol and progesterone in human proliferative endometrium and endometrial carcinoma, Endocrinology 96, 319–328 (1974).Google Scholar
  275. 275.
    M. Haukkamaa and T. Luukkainen, The cytoplasmic progesterone receptor of human endometrium during the menstrual cycle, J. Steroid Biochem. 5, 447–452 (1974).PubMedGoogle Scholar
  276. 276.
    K. Kontula, O. Janne, T. Luukkainen, and R. Vihko, Progesterone binding protein in human myometrium. Influence of metal ions on binding, J. Clin. Endocrinol. Metab. 38, 500–503 (1974).PubMedGoogle Scholar
  277. 277.
    R.G. Smith, C.A. Iramain, V.C. Buttram, Jr., and B.W. O’Malley, Purification of human uterine progesterone receptor, Nature 253, 271–272 (1975).PubMedGoogle Scholar
  278. 278.
    M.R. Sherman, P.L. Corvol, and B.W. O’Malley, Progesterone binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components, J. Biol. Chem. 245, 6085–6096 (1970).PubMedGoogle Scholar
  279. 279.
    D.O. Toft and B.W. O’Malley, Target tissue receptors for progesterone: the influence of estrogen, Endocrinology 90, 1041–1045 (1972).PubMedGoogle Scholar
  280. 280.
    W.T. Schrader, D.O. Toft, and B.W. O’Malley, Progesterone-binding protein of chick oviduct, J. Biol. Chem. 247, 2401–2407(1972).Google Scholar
  281. 281.
    N. Deshpande, R.D. Bulbrook, and F.O. Beizer, An apparent selective accumulation of progesterone by the human breast, Excerpta Med. Int. Congr. Ser. 132, 750–753 (1966).Google Scholar
  282. 282.
    L. Terenius, Estrogen and progestin binders in human and rat mammary carcinoma, Eur. J. Cancer 9, 291–294 (1973).PubMedGoogle Scholar
  283. 283.
    G. Shyamala, Specific cytoplasmic glucocorticoid hormone receptors in lactating mammary glands, Biochemistry 12, 3085–3090 (1973).PubMedGoogle Scholar
  284. 284.
    D.G. Gardner and J.L. Wittliff, Characterization of a distinct glucocorticoid-binding protein in the lactating mammary gland of the rat, Biochim. Biophys. Acta 320, 617–627 (1973).PubMedGoogle Scholar
  285. 285.
    K.B. Horwitz, Progesterone receptors and hormone dependent breast cancer, Doctoral dissertation, University of Texas Southwestern Medical School at Dallas, pp. 80–85 (1975).Google Scholar
  286. 286.
    A.J.W. Hsueh, E.J. Peck, Jr., and J.H. Clark, Progesterone antagonism of estrogen receptor and estradiol-induced uterine growth, Nature 254, 337–338 (1975).PubMedGoogle Scholar
  287. 287.
    D.W. Bullock and G.F. Wellen, Regulation of a specific uterine protein by estradiol and progesterone in ovariectomized rabbits, Proc. Soc. Exp. Biol. Med. 146, 294–298 (1974).PubMedGoogle Scholar
  288. 288.
    E.M. Armstrong and I.A.R. More, Ultrastructural demonstration of the mode of action of an antioestrogen (Tamoxifen), Cytobios 11, 13–16 (1974).Google Scholar
  289. 289.
    J.C. Heuson, C. Waelbroeck, N. Legros, G. Gallez, C. Robyn, and M. L’Hermite, Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-Br-α-Ergocryptine (CB-154), an inhibitor of prolactin secretion, and by Nafoxidine (U-11,100A), an estrogen antagonist, Gynecol. Invest. 2, 130–137 (1971/1972).PubMedGoogle Scholar
  290. 290.
    A.J.W. Hsueh, E.J. Peck, Jr., and J.H. Clark, Control of uterine estrogen receptor levels by progesterone, Endocrinology 98, 438–444 (1976).PubMedGoogle Scholar
  291. 291.
    M.L. Voorhess, Masculinization of the female fetus associated with Noerthindrone-Mestranol therapy during pregnancy, J. Pediatr. 71, 128–131 (1967).PubMedGoogle Scholar
  292. 292.
    G.K. Suchowsky and K. Junkmann, A study of the virilizing effect of progesterone on the female rat fetus, Endocrinology 68, 341–349 (1961).Google Scholar
  293. 293.
    I. Mowszowicz, D. Bieber, K. Chung, L.P. Bullock, and C.W. Bardin, Syandrogenic and antiandrogenic effect of progestins: Comparison with nonprogestational antiandrogens, Endocrinology 95, 1589–1599 (1974).PubMedGoogle Scholar
  294. 294.
    M.S. Fahim and D.G. Hall, Effect of ovarian steroids on hepatic metabolism. I. Progesterone, Am. J. Obstet. Gynecol. 106, 183–186 (1970).PubMedGoogle Scholar
  295. 295.
    L.P. Bullock, P.L. Barthe, I. Mowszowicz, D.N. Orth, and C.W. Bardin, The effect of progestins on submaxillary gland epidermal growth factor: demonstration of androgenic, syandrogenic and antiandrogenic actions, Endocrinology 97, 189–195 (1975).PubMedGoogle Scholar
  296. 296.
    E. Naqvi, M.X. Zarrow, and V.H. Dennberg, Inhibition of androgen-induced precocious puberty by progesterone, Endocrinology 84, 669–670 (1969).PubMedGoogle Scholar
  297. 297.
    K. Kratchwil, In vitro analysis of the hormonal basis for the sexual dimorphism in the embryonic development of the mouse mammary gland, J. Embryol. Exp. Morphol. 25, 141–153 (1971).Google Scholar
  298. 298.
    G.G. Rousseau, J.D. Baxter, and G.M. Tomkins, Glucocorticoid receptors: relations between steroid binding and biological effects, J. Mol. Biol. 67, 99–115 (1972).PubMedGoogle Scholar
  299. 299.
    D.G. Gardner and J.L. Wittliff, Demonstration of a glucocorticoid hormone-receptor complex in the cytoplasm of a hormone-responsive tumour, Br. J. Cancer 27, 441–444 (1973).PubMedGoogle Scholar
  300. 300.
    G. Shyamala, Glucocorticoid receptors in mouse mammary tumors, J. Biol. Chem. 249, 2160–2163 (1974).PubMedGoogle Scholar
  301. 301.
    K.B. Horwitz and W.L. McGuire, Specific progesterone receptors in human breast cancer, Steroids 25, 497–505 (1975).PubMedGoogle Scholar
  302. 302.
    W.W. Thatcher and H.A. Tucker, Adrenal function during prolonged lactation, Proc. Soc. Exp. Biol. Med. 134, 915–918 (1970).PubMedGoogle Scholar
  303. 303.
    W.W. Thatcher and H.A. Tucker, Lactational performance of rats injected with oxytocin cortisol-21-acetate, prolactin and growth hormone during prolonged lactation, Endocrinology 86, 237–240 (1970).PubMedGoogle Scholar
  304. 304.
    T. Oka and Y.J. Topper, Hormone-dependent accumulation of rough endoplasmic reticulum in mouse mammary epithelial cells in vitro, J. Biol. Chem. 246, 7701–7707 (1971).Google Scholar
  305. 305.
    O. Takumi and J. W. Perry, Spermidine as a possible mediator of glucocorticoid effect on milk protein synthesis in mouse mammary epithelium in vitro, J. Biol. Chem. 249, 7647–7652 (1974).Google Scholar
  306. 306.
    R.J.B. King and W.I.P. Mainwaring, Steroid-Cell Interactions, University Park Press, Baltimore (1974).Google Scholar
  307. 307.
    J.D. Baxter, G.G. Rousseau, M.C. Benson, R.L. Garcea, J. Ito, and G.M. Tomkins, Role of DNA and specific cytoplasmic receptors in glucocorticoid action, Proc. Natl. Acad. Sci. U.S.A. 69, 1892–1896 (1972).PubMedGoogle Scholar
  308. 308.
    G.G. Rousseau, S.J. Higgins, J.D. Baxter, and G.M. Tomkins, Nuclear acceptor sites for glucocorticoid receptors, J. Steroid Biochem. 5, 935–939 (1974).Google Scholar
  309. 309.
    N. Defer, B. Dastugue, and J. Kruh, Rat liver chromatin non-histone proteins and glucocorticoid binding, Biochimie 56, 1549–1557 (1974).PubMedGoogle Scholar
  310. 310.
    G.G. Rousseau, Interaction of steroids with hepatoma cells: molecular mechanisms of glucocorticoid hormone action, J. Steroid Biochem. 6, 75–89 (1975).PubMedGoogle Scholar
  311. 311.
    A. Munck and C. Wira, in: Advances in the Biosciences 7 (G. Raspe, ed.), pp. 301–330, Pergamon Vieweg, Oxford (1970).Google Scholar
  312. 312.
    N. Hollander and Y.W. Chiu, In vitro binding of Cortisol-1–2-3H by a substance in the supernatant faction of P1798 mouse lymphosarcoma, Biochem. Biophys. Res. Commun. 25, 291–297 (1966).PubMedGoogle Scholar
  313. 313.
    J.D. Baxter, A.W. Harris, G.M. Tomkins, and M. Cohn, Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity, Science 171, 189–191 (1971).PubMedGoogle Scholar
  314. 314.
    M. Lippman, R. Halterman, S. Perry, B. Leventhal, and E.B. Thompson, Glucocorticoid binding proteins in human leukaemic lymphoblasts, Nature 242, 157–158 (1973).Google Scholar
  315. 315.
    C.H. Sibley and G.M. Tomkins, Mechanisms of steroid resistance, Cell 2, 221–227 (1974).PubMedGoogle Scholar
  316. 316.
    U. Gehring and G.M. Tomkins, A new mechanism for steroid unresponsiveness: loss of nuclear binding activity of a steroid hormone receptor, Cell 2, 301–306 (1974).Google Scholar
  317. 317.
    K.R. Yamamoto, M.R. Stampfer, and G.M. Tompkins, Receptors from glucocorticoid-sensitive lymphoma cells and two classes of insensitive clones: physical and DNA-binding properties, Proc. Natl. Acad. Sci. U.S.A. 71, 3901–3905 (1974).PubMedGoogle Scholar
  318. 318.
    L.L. Sparks, T.A. Daane, T. Hayashida, R.D. Cole, W.R. Lyons, and C.H. Li, The effects of pituitary and adrenal hormones on the growth of a transplanted mammary adenocarcinoma in C3H mice, Cancer 8, 271–284 (1955).PubMedGoogle Scholar
  319. 319.
    R. Hilf, I. Michel, C. Bell, J.J. Freeman, and A. Borman, Biochemical and morphologic properties of a new lactating mammary tumor line in the rat, Cancer Res. 25, 286–299 (1965).PubMedGoogle Scholar
  320. 320.
    L. Kornel, On the effects and the mechanism of corticosteroids in normal and neoplastic target tissue: Findings and hypotheses, Acta Endocrinol. 74, 1–45 (1973).Google Scholar
  321. 321.
    C.M. McGrath, Replication of mammary tumor virus in tumor cell cultures: Dependence on hormone-induced cellular organization, J. Natl. Cancer Inst. 47, 455–467 (1971).PubMedGoogle Scholar
  322. 322.
    H.A. Young, E.M. Scolnick, and W.P. Parks, Glucocorticoid-receptor interactions and induction of murine mammary tumor virus, J. Biol. Chem. 250, 3337–3343 (1975).PubMedGoogle Scholar
  323. 323.
    A. Pihl, S. Sander, I. Brennhoud, and S. Olsens, in: Estrogen Receptors in Human Breast Cancer (W.L. McGuire, P.P. Carbone, and E.P. Vollmer, eds.), pp. 193–203, Raven Press, New York (1975).Google Scholar
  324. 324.
    M.B. Lipsett, Why corticoids are effective against a wide variety of cancers, Ann. N. Y. Acad. Sci. 230, 489–490 (1974).PubMedGoogle Scholar
  325. 325.
    H.A. Tucker, B.L. Larson, and J. Gorski, Cortisol binding in cultured bovine mammary cells, Endocrinology 89, 152–160 (1971).PubMedGoogle Scholar
  326. 326.
    R.W. Turnell, P.C. Beers, and J.L. Wittliff, Glucocorticoid-binding macromolecules in the lactating mammary gland of the vole, Endocrinology 95, 1770–1773 (1974).PubMedGoogle Scholar
  327. 327.
    J.E. Goral and J.L. Wittliff, Comparison of glucocorticoid-binding proteins in normal and neoplastic mammary tissues of the rat, Biochemistry 14, 2944–2952 (1975).PubMedGoogle Scholar
  328. 328.
    G. Shyamala, Glucocorticoid receptors in mouse mammary tumors: Specific binding to nuclear components, Biochemistry 14, 437–444 (1975).PubMedGoogle Scholar
  329. 329.
    E.E. Baulieu, The action of hormone metabolites: A new concept in endocrinology, Ann. Clin. Res. 2, 246–250 (1970).PubMedGoogle Scholar
  330. 330.
    L.P. Bullock and C.W. Bardin, Androgen receptors in mouse kidney: A study of male, female and androgen-insensitive (tfmly) mice, Endocrinology 94, 746–756 (1974).PubMedGoogle Scholar
  331. 331.
    L.P. Bullock and C.W. Bardin, In vivo androgen retention in mouse kidney, Steroids 25, 107–119 (1975).PubMedGoogle Scholar
  332. 332.
    U. Gehring, G.M. Tomkins, and S. Ohno, Effect of androgen insensitivity mutation on a cytoplasmic receptor for dihydrotestosterone, Nature 232, 106–107 (1971).Google Scholar
  333. 333.
    B. Attardi and S. Ohno, Cytosol androgen receptor from kidney of normal and testicular feminized (Tfm) mice, Cell 2, 205–212 (1974).PubMedGoogle Scholar
  334. 334.
    L.P. Bullock and C.W. Bardin, Androgen receptors in testicular feminization, J. Clin. Endocrinol. Metab. 35, 935–937 (1972).PubMedGoogle Scholar
  335. 335.
    L.P. Bullock and C.W. Bardin, In vivo and in vitro testosterone metabolism by the androgen insensitive rat, J. Steroid Biochem. 4, 139–151 (1973).PubMedGoogle Scholar
  336. 336.
    J. Imperato-McGinley, L. Guerrero, T. Gautier, and R.E. Peterson, Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism, Science 186, 1213–1215 (1974).PubMedGoogle Scholar
  337. 337.
    W. Mainwaring and F.R. Mangan, A study of the androgen receptors in a variety of androgen-sensitive tissues, J. Endocrinol. 59, 121–139 (1973).PubMedGoogle Scholar
  338. 338.
    S.A. Shain and L.R. Axelrod, Reduced high affinity 5-α-dihydrotestosterone receptor capacity in the ventral prostate of the aging rat, Steroids 21, 801–812 (1973).PubMedGoogle Scholar
  339. 339.
    I. Jung and E.E. Baulieu, Neo-nuclear androgen receptor in rat ventral prostate, Biochimie 53, 807–817 (1971).PubMedGoogle Scholar
  340. 340.
    J.N. Sullivan and C.A. Strott, Evidence for an androgen-independent mechanism regulating the levels of receptor in target tissue, J. Biol. Chem. 248, 3202–3208 (1973).PubMedGoogle Scholar
  341. 341.
    N. Bruchovsky and S. Craven, Prostatic involution: Effect on androgen-receptors and intracellular androgen transport, Biochem. Biophys. Res. Commun. 62, 837–843 (1975).PubMedGoogle Scholar
  342. 342.
    S. Liao, D.K. Howell, and T.-M. Chang, Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5-α-dihydrotestosterone in rat ventral prostate, Endocrinology 94, 1205–1209 (1974).PubMedGoogle Scholar
  343. 343.
    E.A. Peets, M.F. Henson, and R. Neri, On the mechanism of the antiandrogenic action of flutamide (α,α,α-Tiifluoro-2-methyl-4′-nitro-m-propionotoluidide) in the rat, Endocrinology 94, 532–540 (1974).PubMedGoogle Scholar
  344. 344.
    L. Terenius, Affinities of progestogen and estrogen receptors in rabbit uterus for synthetic progestens, Steroids 23, 909–919 (1974).Google Scholar
  345. 345.
    C. Huggins, L.C. Grand, and F.P. Brillantes, Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression, Nature 189, 204–207 (1961).PubMedGoogle Scholar
  346. 346.
    J. Furth, Vistas in the etiology and pathogenesis of tumors, Fed. Proc. Fed. Am. Soc. Exp. Biol. 20, 865–873 (1961).Google Scholar
  347. 347.
    E. Heise and M. Gorlich, Growth and therapy of mammary tumors induced by 7,12-Dimethylbenzanthracene in rats, Br. J. Cancer 20, 539–545 (1966).PubMedGoogle Scholar
  348. 348.
    Cooperative Breast Cancer Group, Testosterone propionate therapy in breast cancer, J. Am. Med. Assoc. 188, 1069–1072 (1964).Google Scholar
  349. 349.
    I.S. Goldenberg, N. Waters, R.S. Ravdin, F.J. Ansfield, and A. Segaloff, Androgenic therapy for advanced breast cancer in women, J. Am. Med. Assoc. 223, 1267–1268 (1973).Google Scholar
  350. 350.
    H. Volk, R.J. Deupree, I.S. Goldenberg, R.C. Wilde, R.A. Carabasi, and G.C. Escher, A dose response evaluation of Delta-1-testololactone in advanced breast cancer, Cancer 33, 9–13 (1974).PubMedGoogle Scholar
  351. 351.
    W.L. McGuire, Current status of estrogen receptors in human breast cancer, Cancer 36, 638–644 (1975).PubMedGoogle Scholar
  352. 352.
    M. Lyon and P.H. Glenister, Evidence from Tfm/0 that androgen is inessential for reproduction in female mice, Nature 247, 366–367 (1974).PubMedGoogle Scholar
  353. 353.
    S. Ohno, L. Christian, and B. Attardi, Role of testosterone in normal female function, Nature (London) New Biol. 243 119–120 (1973).Google Scholar
  354. 354.
    W. Elger and F. Neumann, The role of androgens in differentiation of the mammary gland in male mouse fetuses, Proc. Soc. Exp. Biol. Med. 123, 637–640 (1966).PubMedGoogle Scholar
  355. 355.
    F. Neumann and W. Elger, The effect of the anti-androgen l,2α-methylene-6-chloro-Δ4,6-pregradiene-17α-OL-3,20-dione-17α-acetate (cyproterone acetate) on the development of the mammary glands of male foetal rats, J. Endocrinol. 36, 347–353 (1966).PubMedGoogle Scholar
  356. 356.
    R.K. Wagner, L. Gorlich, and P. W. Jungblut, Dihydrotestosterone receptor in human mammary cancer, Acta Endocrinol. 173, 65 (1973).Google Scholar
  357. 357.
    J.P. Persijn, C.B. Korsten, and E. Engelsman, Oestrogen and androgen receptors in breast cancer and response to endocrine therapy, Br. Med. J. 4, 503 (1975).PubMedGoogle Scholar
  358. 358.
    J. Poortman, J.A.C. Pregnen, F. Schwarz, and J.H.H. Thijssen, Interaction of Δ5-androstene-3β-17β-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue, J. Clin. Endocrinol. Metab. 40, 373–379 (1975).PubMedGoogle Scholar
  359. 359.
    M.E. Lippman, G. Bolan and K. Huff, Human breast cancer responsive to androgen in long term tissue culture, Nature 258, 339–341 (1975).PubMedGoogle Scholar
  360. 360.
    W.R. Miller, D. McDonald, A.P.M. Forrest, and A.A. Shivas, Metabolism of androgens by human breast tissue, Lancet 1, 912–913 (1973).PubMedGoogle Scholar
  361. 361.
    L. Raith, A. Wirtz, M. Wiedemann, and H.J. Karl, Metabolism of testosterone and androstendione in human breast carcinoma and its relation to sexual hormone receptors, Acta Endocrinol. 177, 28–29 (1973).Google Scholar
  362. 362.
    J.S. Jenkins and S. Ash, Metabolism of testosterone by human breast tumors, Lancet 2, 513–514 (1972).PubMedGoogle Scholar
  363. 363.
    L.I. Rose, R.H. Underwood, M.T. Dunning, G. Williams, and G.S. Pinkus, Testosterone metabolism in benign and malignant breast lesions, Cancer 36, 399–403 (1975).PubMedGoogle Scholar
  364. 364.
    N. Bruchovsky and J.W. Meakin, The metabolism and binding of testosterone in androgen-dependent and autonomous transplantable mouse mammary tumors, Cancer Res. 33, 1689–1695 (1973).PubMedGoogle Scholar
  365. 365.
    K. Yamaguchi, H. Kasai, T. Minesita, K. Kotoh, and K. Matsumoto, 5α-Reduction and binding of testosterone in androgen-dependent and independent mouse mammary tumors, Endocrinology 95, 1424–1430 (1974).PubMedGoogle Scholar
  366. 366.
    N. Bruchovsky, D.J.A. Sutherland, J.W. Meakin, and T. Minesita, Androgen receptors: relationship to growth response and to intracellular androgen transport in nine variant lines of the Shionogi mouse mammary tumor, Biochim. Biophys. Acta 381, 61–71 (1975).PubMedGoogle Scholar
  367. 367.
    J.A. Smith and R.J.B. King, Effects of steroids on growth of an androgen-dependent mouse mammary carcinoma in cell culture, Exp. Cell Res. 73, 351–359 (1972).PubMedGoogle Scholar
  368. 368.
    D.J.A. Sutherland, E.C. Robins, and J.W. Meakin, Effects of androgens on Shionogi carcinoma 115 cells in vitro, J. Natl. Cancer Inst. 52, 37–48 (1974).PubMedGoogle Scholar
  369. 369.
    J. Gordon, J.A. Smith, and R.J.B. King, Metabolism and binding of androgens by mouse mammary tumour cells in culture, Mol. Cell. Endocrinol. 1, 259–270 (1974).Google Scholar
  370. 370.
    S.K. Quadri, G.S. Kledzik, and J. Meites, Counteraction by prolactin of androgen-induced inhibition of mammary tumor growth in rats, J. Natl. Cancer Inst. 52, 875–878 (1974).PubMedGoogle Scholar
  371. 371.
    P.S. Kalra, C.P. Fawcett, L. Krulich, and S.M. McCann, The effects of gonadal steroids on plasma gonadotropins and prolactin in the rat, Endocrinology 92, 1256–1268 (1973).PubMedGoogle Scholar
  372. 372.
    Y.J. Abulhajj, Metabolism of dehydroepiandrosterone by hormone dependent and hormone independent human breast carcinoma, Steroids 26, 488–500 (1975).Google Scholar
  373. 373.
    A. Nimrod and K.J. Ryan, Aromatization of androgens by human abdominal and breast fat tissue, J. Clin. Endocrinol. Metab. 40, 367–372 (1975).PubMedGoogle Scholar
  374. 374.
    H. Rochefort, F. Lignon, and F. Capony, Formation of estrogen nuclear receptor in uterus: Effect of androgens, estrone and nafoxidine, Biochem. Biophys. Res. Commun. 47, 662–676 (1972).PubMedGoogle Scholar
  375. 375.
    T.S. Ruh and M.F. Ruh, Androgen induction of a specific uterine protein, Endocrinology 97, 1144–1150 (1975).PubMedGoogle Scholar
  376. 376.
    W.N. Schmidt, M.A. Sadler, and B.S. Katzenellenbogen, Androgen-uterine interaction: Nuclear translocation of the estrogen receptor and induction of the synthesis of the uterine-induced protein (IP) by high concentrations of androgens in vitro but not in vivo, Endocrinology 98, 702–716 (1976).Google Scholar
  377. 377.
    H. Rochefort, in: Research on Steroids Pergamon Vieweg, Oxford (1976), in press.Google Scholar
  378. 378.
    N. Deshpande, V. Jensen, R.D. Bulbrook, T. Berne, and F. Ellis, Accumulation of tritiated oestradiol by human breast tissue, Steroids 10, 219–232 (1967).PubMedGoogle Scholar
  379. 379.
    B.G. Mobbs, The effect of testosterone treatment on the uptake of 3H-oestradiol-17β by dimethylbenzanthracene-induced rat mammary tumors, J. Endocrinol. 48, 293–294 (1970).PubMedGoogle Scholar
  380. 380.
    D.T. Zava and W.L. McGuire, Androgen induced depletion of estrogen receptor in rat mammary tumors, Cancer Res. (1977), in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1977

Authors and Affiliations

  • William Leo McGuire
    • 1
  1. 1.Department of MedicineUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations